Particle Cloud Biotech Completes Series B Funding Round to Advance 3D-Printed Regenerative Bone Implants

Investment Circle – Xi’an Entrepreneurship (XianDream.com) reported that on April 17, Xi’an Particle Cloud Biotechnology Co., Ltd. (hereinafter referred to as “Particle Cloud”) announced the completion of its Series B financing, with Detong Capital as the investor; the specific amount was not disclosed.

Particle Cloud, established in 2014, specializes in providing advanced materials, innovative products, and intelligent equipment for the life and health sectors. The company has long been dedicated to the core research and development of 3D-printed regenerative artificial bone technologies and has established the world’s first GMP-compliant production line for 3D-printed artificial bone.

In terms of technology, the bioceramic 3D printer independently developed by Particle Cloud can precisely and personally customize artificial bones that are biodegradable, osteoinductive in physicochemical properties, and biomimetic in appearance and structure. On February 2, 2018, it achieved successful clinical trials at Xijing Hospital, marking a significant breakthrough in solving the international challenge of personalized repair of load-bearing long-segment bone defects using 3D printing technology, thereby filling the technological gap in this field in China.

It is reported that Particle Cloud completed its Pre-A round of financing at the end of 2016, with joint investment from Beijing China Fortune Land Development Industrial Investment Fund, Qingwang Technology Park Development (Gu'an) Co., Ltd., Shaanxi High-End Equipment High-Tech Venture Capital Fund, Shaanxi Additive Manufacturing Venture Capital Fund, and Shaanxi Biopharmaceutical Venture Capital Fund.